WO2001041701A3 - The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist - Google Patents

The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist Download PDF

Info

Publication number
WO2001041701A3
WO2001041701A3 PCT/DK2000/000671 DK0000671W WO0141701A3 WO 2001041701 A3 WO2001041701 A3 WO 2001041701A3 DK 0000671 W DK0000671 W DK 0000671W WO 0141701 A3 WO0141701 A3 WO 0141701A3
Authority
WO
WIPO (PCT)
Prior art keywords
serotonin reuptake
agonist
combination
reuptake inhibitor
inverse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2000/000671
Other languages
French (fr)
Other versions
WO2001041701A2 (en
Inventor
Thomas Ivo Franciscus Cremers
Haakan Wilhelm Wikstroem
Boer Johan Antonie Den
Fokko Jan Bosker
Bernard Hendrik Corn Westerink
Klaus Peter Boegesoe
Sandra Hogg
Arne Moerk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UA2002065005A priority Critical patent/UA77650C2/en
Priority to AU18511/01A priority patent/AU1851101A/en
Priority to DE60025398T priority patent/DE60025398T2/en
Priority to IL14999400A priority patent/IL149994A0/en
Priority to BR0016385-6A priority patent/BR0016385A/en
Priority to HRP20020527 priority patent/HRP20020527A2/en
Priority to MXPA02005613A priority patent/MXPA02005613A/en
Priority to SI200030820T priority patent/SI1237553T1/en
Priority to CA002393470A priority patent/CA2393470A1/en
Priority to SK796-2002A priority patent/SK7962002A3/en
Priority to JP2001542871A priority patent/JP2003516326A/en
Priority to MEP-62/08A priority patent/MEP6208A/en
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Priority to EA200200649A priority patent/EA006391B1/en
Priority to PL00356402A priority patent/PL356402A1/en
Priority to HU0203586A priority patent/HUP0203586A3/en
Priority to EP00981174A priority patent/EP1237553B1/en
Publication of WO2001041701A2 publication Critical patent/WO2001041701A2/en
Publication of WO2001041701A3 publication Critical patent/WO2001041701A3/en
Priority to IS6404A priority patent/IS2227B/en
Priority to IL149994A priority patent/IL149994A/en
Priority to NO20022657A priority patent/NO20022657L/en
Priority to US10/165,196 priority patent/US20030032636A1/en
Anticipated expiration legal-status Critical
Priority to BG106895A priority patent/BG106895A/en
Priority to CY20061100431T priority patent/CY1105014T1/en
Priority to US11/539,100 priority patent/US20070105843A1/en
Priority to US12/406,226 priority patent/US20090176808A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9413—Dopamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)

Abstract

The present invention relates to the use of compounds and compositions of compounds having serotonin reuptake inhibiting activity and 5-HT2C antagonistic, partial agonistic or inverse agonistic activity for the for the treatment of depression and other affective disorders. The combined serotonin reuptake inhibiting effect and the 5-HT2C antagonistic, partial agonistic or inverse agonistic effect may reside within the same chemical compound or in two different chemical compounds.
PCT/DK2000/000671 1999-12-06 2000-12-06 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist Ceased WO2001041701A2 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
UA2002065005A UA77650C2 (en) 1999-12-06 2000-06-12 Use of serotonin reuptake inhibitor in combination with deramcyclane
EA200200649A EA006391B1 (en) 1999-12-06 2000-12-06 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist
IL14999400A IL149994A0 (en) 1999-12-06 2000-12-06 THE COMBINATION OF SEROTONIN REUPTAKE INHIBITOR AND A 5-HT2c ANTAGONIST, INVERSE AGONIST OR PARTIAL AGONIST
BR0016385-6A BR0016385A (en) 1999-12-06 2000-12-06 Compounds or combinations thereof which have seratonin reuptake inhibitory activity and a 5-ht2c antagonist, inverse agonist or partial agonist; use thereof; pharmaceutical composition and method
HU0203586A HUP0203586A3 (en) 1999-12-06 2000-12-06 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist
MXPA02005613A MXPA02005613A (en) 1999-12-06 2000-12-06 The combination of a serotonin reuptake inhibitor and a 5-ht2c.
SI200030820T SI1237553T1 (en) 1999-12-06 2000-12-06 The combination of a serotonin reuptake inhibitor and a 5-ht 2c? antagonist, inverse agonist or partial agonist
CA002393470A CA2393470A1 (en) 1999-12-06 2000-12-06 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist
SK796-2002A SK7962002A3 (en) 1999-12-06 2000-12-06 The use of 5-ht2c receptor antagonist and pharmaceutical composition comprising the same
JP2001542871A JP2003516326A (en) 1999-12-06 2000-12-06 Combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist, or semi-agonist
MEP-62/08A MEP6208A (en) 1999-12-06 2000-12-06 The combination of a serotonin reuptake inhibitor and a 5-ht¿2c? antagonist, inverse agonist or partial agonist
DE60025398T DE60025398T2 (en) 1999-12-06 2000-12-06 COMBINATION OF A SEROTONIN RECOVERY INHIBITOR AND A 5-HT2C ANTAGONIST, INVERSE AGONIST OR A PARTICULATE AGONIST
PL00356402A PL356402A1 (en) 1999-12-06 2000-12-06 The combination of a serotonin reuptake inhibitor and a 5-ht2c
AU18511/01A AU1851101A (en) 1999-12-06 2000-12-06 The combination of a serotonin reuptake inhibitor and a 5-HT2c antagonist, inverse agonist or partial agonist
HRP20020527 HRP20020527A2 (en) 1999-12-06 2000-12-06 The combination of a serotonin reuptake inhibitor and a 5-ht<sub>2c</sub> antagonist, inverse agonist or partial agonist
EP00981174A EP1237553B1 (en) 1999-12-06 2000-12-06 The combination of a serotonin reuptake inhibitor and a 5-ht 2c? antagonist, inverse agonist or partial agonist
IS6404A IS2227B (en) 1999-12-06 2002-05-31 The mixture of serotonin reuptake inhibitors and 5-HT2C antagonists, reversers or partial actions.
IL149994A IL149994A (en) 1999-12-06 2002-06-03 Use of a combination of a compound
NO20022657A NO20022657L (en) 1999-12-06 2002-06-05 The combination of a serotonin reuptake inhibitor and a 5-HT <N> 2C </N> antagonist, inverse agonist or partial agonist
US10/165,196 US20030032636A1 (en) 1999-12-06 2002-06-06 Combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist
BG106895A BG106895A (en) 1999-12-06 2002-07-02 The combination of a serotonin reuptake inhibitor as a 5-ht2c antagonist, inverse agonist or partial agonist
CY20061100431T CY1105014T1 (en) 1999-12-06 2006-03-28 THE COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND A 5-HT2C ANTAGONIST, INVERSE AGENT OR PARTIAL AGENT
US11/539,100 US20070105843A1 (en) 1999-12-06 2006-10-05 Combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist
US12/406,226 US20090176808A1 (en) 1999-12-06 2009-03-18 combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16924599P 1999-12-06 1999-12-06
US60/169,245 1999-12-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/731,411 Continuation US20020103249A1 (en) 1999-12-06 2000-12-06 Combination of a serotonin reuptake inhibitor and irindalone

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/165,196 Continuation US20030032636A1 (en) 1999-12-06 2002-06-06 Combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist

Publications (2)

Publication Number Publication Date
WO2001041701A2 WO2001041701A2 (en) 2001-06-14
WO2001041701A3 true WO2001041701A3 (en) 2001-12-13

Family

ID=22614803

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/DK2000/000667 Ceased WO2001041766A1 (en) 1999-12-06 2000-12-04 The combination of a serotonin reuptake inhibitor and irindalone
PCT/DK2000/000671 Ceased WO2001041701A2 (en) 1999-12-06 2000-12-06 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/DK2000/000667 Ceased WO2001041766A1 (en) 1999-12-06 2000-12-04 The combination of a serotonin reuptake inhibitor and irindalone

Country Status (33)

Country Link
US (4) US20020103249A1 (en)
EP (2) EP2036564A1 (en)
JP (1) JP2003516326A (en)
KR (1) KR100832026B1 (en)
CN (2) CN101406465A (en)
AT (1) ATE314849T1 (en)
AU (2) AU1850801A (en)
BG (1) BG106895A (en)
BR (1) BR0016385A (en)
CA (1) CA2393470A1 (en)
CO (1) CO5251409A1 (en)
CY (1) CY1105014T1 (en)
CZ (1) CZ20021961A3 (en)
DE (1) DE60025398T2 (en)
DK (1) DK1237553T3 (en)
EA (1) EA006391B1 (en)
ES (1) ES2255519T3 (en)
HR (1) HRP20020527A2 (en)
HU (1) HUP0203586A3 (en)
IL (2) IL149994A0 (en)
IS (1) IS2227B (en)
ME (1) MEP6208A (en)
MX (1) MXPA02005613A (en)
NO (1) NO20022657L (en)
NZ (1) NZ545907A (en)
PL (1) PL356402A1 (en)
PT (1) PT1237553E (en)
SK (1) SK7962002A3 (en)
TR (1) TR200201512T2 (en)
UA (1) UA77650C2 (en)
WO (2) WO2001041766A1 (en)
YU (1) YU41902A (en)
ZA (1) ZA200204391B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229997B2 (en) 2002-05-17 2007-06-12 Biovitrum Ab Compounds and their use

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (en) * 1999-07-08 2002-06-12 Lundbeck & Co As H TREATMENT OF NEUROTIC DISORDERS
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
US6589996B2 (en) 2000-03-17 2003-07-08 Orion Corporation Treatment of disorders relating to the serotonergic system
WO2002043727A1 (en) * 2000-11-28 2002-06-06 Orion Corporation Treatment of psychiatric disorders with trimethyl-bicyclo[2.2.1]heptane derivatives
US6335372B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Treatment of obsessive compulsive disorder
FI20002612A0 (en) * 2000-11-28 2000-11-28 Orion Yhtymae Oyj Combination therapy for the treatment of disorders in serotonin turnover
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
EA200301195A1 (en) * 2001-05-01 2004-04-29 Х. Лундбекк А/С APPLICATION OF ENANTIOMERALLY CLEAN ESCYTAL PREMA
GB0118892D0 (en) * 2001-08-02 2001-09-26 Vernalis Res Ltd Method of treatment
EP2260844A1 (en) * 2003-05-27 2010-12-15 Merz Pharma GmbH & Co. KGaA Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AR047553A1 (en) * 2003-07-04 2006-01-25 Lundbeck & Co As H THE COMBINATION OF A SEROTONINE AND AGOMELATINE REABSORTION INHIBITOR
EP1500391A1 (en) * 2003-07-24 2005-01-26 Neuro3D Therapeutic use of bicycloheptane derivatives
SI1668014T1 (en) 2003-09-17 2009-06-30 Janssen Pharmaceutica Nv Fused heterocyclic compounds as serotonin receptor modulators
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
WO2005053703A1 (en) * 2003-12-02 2005-06-16 Leslie James Sheldon Combination therapy for dementia, depression and apathy
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050241110A1 (en) * 2004-04-09 2005-11-03 Bruce Baker Ergonomic handles, especially for garden tools
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
WO2007107165A1 (en) * 2006-03-22 2007-09-27 H. Lundbeck A/S Method for identifying compounds for the treatment of depression
EP2044043B2 (en) 2006-06-16 2021-03-03 H. Lundbeck A/S 1- ý[- (2, 4-dimethylphenylsulfanyl) -phenyl]piperazine hydrobromide as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
CN101815519B (en) * 2007-08-03 2013-08-21 吉瑞工厂 Pharmaceutical compositions comprising dopamine receptor ligands and methods of treatment using dopamine receptor ligands
WO2009082268A2 (en) 2007-12-21 2009-07-02 Alla Chem, Llc LIGANDS OF α-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF
WO2010006231A1 (en) * 2008-07-10 2010-01-14 Ore Pharmaceuticals Inc. Treating inflammation and related conditions with irindalone
CN103097357B (en) 2010-07-15 2015-01-28 大日本住友制药株式会社 Pyrazole compound
EP2629615B1 (en) 2010-10-22 2018-10-10 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
WO2014046544A1 (en) 2012-09-21 2014-03-27 Aapa B.V. Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators
WO2014144231A1 (en) 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
WO2016205631A1 (en) * 2015-06-17 2016-12-22 Massachusetts Institute Of Technology Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders
CN107556206A (en) * 2016-06-30 2018-01-09 陕西合成药业股份有限公司 A kind of new 5 serotonin reuptake inhibitor class compound and preparation method thereof and application medically
US11478467B2 (en) 2017-05-04 2022-10-25 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
CN119470729B (en) * 2025-01-15 2025-04-29 山东英盛生物技术有限公司 Method for quantitatively detecting mycophenolic acid in trace blood by high performance liquid chromatography-tandem mass spectrometry

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2303303A (en) * 1995-07-13 1997-02-19 American Home Prod 5HT-1A and 5HT-2 antagonists for treating side-effects of serotonin re-uptake inhibitors
EP0813873A1 (en) * 1996-06-19 1997-12-29 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US5786157A (en) * 1990-05-08 1998-07-28 Synapatic Pharmaceutical Corporation DNA encoding human 5-HT1D receptors and uses thereof
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
EP0966976A1 (en) * 1998-06-22 1999-12-29 Centeon Pharma GmbH Method for removal of HIV from a solution
DE19900673A1 (en) * 1999-01-11 2000-07-13 Basf Ag Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
AU4704693A (en) 1992-08-20 1994-03-15 Smithkline Beecham Plc Condensed indole derivatives as 5HT-2C and 5HT-2B antagonists
WO1994014801A1 (en) 1992-12-29 1994-07-07 Smithkline Beecham Plc Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
PT684237E (en) * 1993-02-10 2000-04-28 Yamanouchi Pharma Co Ltd MORPHINE DERIVATIVES
GB9313913D0 (en) 1993-07-06 1993-08-18 Smithkline Beecham Plc Novel compounds
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0773942A1 (en) * 1994-07-26 1997-05-21 Pfizer Inc. 4-indole derivatives as serotonin agonists and antagonists
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of a drug by a serotonin 1A receptor antagonist
US5972937A (en) 1995-02-02 1999-10-26 Smithkline Beecham P.L.C. Heterocyclic compounds possessing 5HT2C receptor antagonist activity
SE9501567D0 (en) * 1995-04-27 1995-04-27 Astra Ab A new combination
GB9511355D0 (en) 1995-06-06 1995-08-02 Fujisawa Pharmaceutical Co Urea derivatives
GB9517559D0 (en) 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
FR2744449B1 (en) 1996-02-02 1998-04-24 Pf Medicament NOVEL AROMATIC PIPERAZINES DERIVED FROM SUBSTITUTED CYCLOAZANES, AS WELL AS THEIR PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS MEDICAMENTS
GB9607219D0 (en) 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
EP0892804B1 (en) 1996-04-12 2002-08-28 Janssen Pharmaceutica N.V. Isoxazolidine derivatives
SE9703375D0 (en) * 1997-09-18 1997-09-18 Astra Ab A new combination
BR9911049A (en) * 1998-05-22 2001-02-06 Lilly Co Eli Combination therapy for treatment of resistant depression
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
IL139591A0 (en) * 1998-05-29 2002-02-10 Lilly Co Eli Combination therapy for treatment of bipolar disorders
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786157A (en) * 1990-05-08 1998-07-28 Synapatic Pharmaceutical Corporation DNA encoding human 5-HT1D receptors and uses thereof
GB2303303A (en) * 1995-07-13 1997-02-19 American Home Prod 5HT-1A and 5HT-2 antagonists for treating side-effects of serotonin re-uptake inhibitors
EP0813873A1 (en) * 1996-06-19 1997-12-29 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
EP0966976A1 (en) * 1998-06-22 1999-12-29 Centeon Pharma GmbH Method for removal of HIV from a solution
DE19900673A1 (en) * 1999-01-11 2000-07-13 Basf Ag Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AGNES BESSON: "Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain", EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 10, 2000, pages 177 - 188, XP001055741 *
CONNIE SANCHEZ ET AL.: "Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding", CELLULAR AND MOLECULAR NEUROBIOLOGY, vol. 19, no. 4, 1999, pages 467 - 489, XP000861810 *
L. LAURITZEN ET AL.: "Combined treatment with imipramine and mianserin", PHARMACOPSYCHIAT., vol. 25, 1992, pages 182 - 186, XP002951440 *
MICHAEL MAES ET AL.: "Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance", JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol. 19, no. 2, 1999, pages 177 - 182, XP001055722 *
PAUL J. GOODNICK ET AL.: "New antidepressant agents: Recent pharmacological developments leading to improved efficacy", EXP. OPIN. INVEST. DRUGS, vol. 4, no. 10, 1995, pages 935 - 943, XP001018332 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229997B2 (en) 2002-05-17 2007-06-12 Biovitrum Ab Compounds and their use

Also Published As

Publication number Publication date
EP1237553A2 (en) 2002-09-11
KR100832026B1 (en) 2008-05-23
PT1237553E (en) 2006-05-31
BG106895A (en) 2003-04-30
NO20022657D0 (en) 2002-06-05
US20030032636A1 (en) 2003-02-13
JP2003516326A (en) 2003-05-13
CO5251409A1 (en) 2003-02-28
CA2393470A1 (en) 2001-06-14
CN101406465A (en) 2009-04-15
EA006391B1 (en) 2005-12-29
DE60025398D1 (en) 2006-03-30
US20070105843A1 (en) 2007-05-10
CN1433313A (en) 2003-07-30
NZ545907A (en) 2007-07-27
EP2036564A1 (en) 2009-03-18
UA77650C2 (en) 2007-01-15
MXPA02005613A (en) 2002-12-13
KR20020060987A (en) 2002-07-19
TR200201512T2 (en) 2002-09-23
AU1850801A (en) 2001-06-18
EA200200649A1 (en) 2002-12-26
ZA200204391B (en) 2003-11-26
US20020103249A1 (en) 2002-08-01
WO2001041701A2 (en) 2001-06-14
IS6404A (en) 2002-05-31
AU1851101A (en) 2001-06-18
HUP0203586A3 (en) 2005-02-28
DE60025398T2 (en) 2006-08-03
IS2227B (en) 2007-04-15
WO2001041766A1 (en) 2001-06-14
PL356402A1 (en) 2004-06-28
YU41902A (en) 2005-06-10
SK7962002A3 (en) 2002-09-10
ATE314849T1 (en) 2006-02-15
HUP0203586A2 (en) 2003-03-28
CY1105014T1 (en) 2009-11-04
EP1237553B1 (en) 2006-01-04
CZ20021961A3 (en) 2002-11-13
ES2255519T3 (en) 2006-07-01
BR0016385A (en) 2003-02-18
HRP20020527A2 (en) 2004-12-31
US20090176808A1 (en) 2009-07-09
DK1237553T3 (en) 2006-05-15
IL149994A0 (en) 2002-12-01
MEP6208A (en) 2010-02-10
NO20022657L (en) 2002-07-26
IL149994A (en) 2007-07-24

Similar Documents

Publication Publication Date Title
WO2001041701A3 (en) The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist
WO2002072536A8 (en) Urea derivatives having vanilloid receptor (vr1) antagonist activity
WO2004047838A3 (en) Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents
WO2003049702A3 (en) Vanilloid receptor ligands and their use in treatments
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
AR020345A1 (en) PIRAZOL-CARBOXANILIDS, PROCEDURE FOR OBTAINING, COMPOSITIONS, USE OF SUCH COMPOUNDS AND PROCEDURE FOR THE FIGHT AGAINST INDESEABLE MICROORGANISMS, AND PROCEDURE FOR OBTAINING SUCH COMPOSITIONS.
CA2400447A1 (en) Kinase inhibitors
PL361004A1 (en) Use of moo3 as corrosion inhibitor, and coating composition containing such an inhibitor
WO2003095455A3 (en) Substituted pyrazolopyrimidines
DE60324544D1 (en) MUSCARIN ANTAGONISTS
WO2003057145A3 (en) SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
MXPA03009750A (en) Chemical compounds.
DE60206164D1 (en) TRISUBSTITUTED-N - ((1S) -1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL) BENZAMIDES INHIBITING P2X3 AND P2X2 / 3 CONTAINING RECEPTORS
WO2003068207A3 (en) Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity
MY135916A (en) Use of certain affinity nmda antagonists as antidepressants
WO2000002551A3 (en) Methods and compounds for treating depression
PT1463735E (en) Imidazo¬2,1-b -1,3,4-thiadiazole sulfonamides
CA2356985A1 (en) 5ht1 antagonists for antidepressant therapy
WO2003057140A3 (en) Composition and methods for treatment of neurological disorders
WO2002051848A3 (en) Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
EP1396267A3 (en) The combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist
WO2003051291A3 (en) Substituted 5-hydroxy-indole compounds for the treatment of glaucoma
WO2002024727A3 (en) New inhibitors of iapp fibril formation and uses thereof
EP1917979A4 (en) Therapeutic agent for atrial fibrillation
UA83187C2 (en) Aryl- and heteroarylpiperazines

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200200613

Country of ref document: VN

Ref document number: P-419/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 149994

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2393470

Country of ref document: CA

Ref document number: 7962002

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2001 542871

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2002-1961

Country of ref document: CZ

Ref document number: 10165196

Country of ref document: US

Ref document number: 18511/01

Country of ref document: AU

Ref document number: PA/a/2002/005613

Country of ref document: MX

Ref document number: 2002/01512

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 2000981174

Country of ref document: EP

Ref document number: 1020027007231

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 519479

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: P20020527A

Country of ref document: HR

ENP Entry into the national phase

Ref document number: 2000 106895

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/1026/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200200649

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020027007231

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 008188270

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2000981174

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-1961

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2000981174

Country of ref document: EP